Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.


NDAQ:EQ - Post by User

Equillium Inc
<< Previous
 Bullboard Posts
User Avatar Image
(114)
•••
Post by whytestockson Jun 04, 2024 7:15pm
18 Views
Post# 36072219

Equillium Announces Positive Topline Data from Phase 2 Study

Equillium Announces Positive Topline Data from Phase 2 Study
News; $EQ Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata20% of all subjects that completed the 24-week treatment period achieved SALT &#x2264; 20 29% of completed subjects with moderate to severe disease (baseline SALT 35 to &lt;95) achieved SALT &#x2264; 20 EQ101 was well tolerated in subjects with alopecia areata with no serious adve...EQ - Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities